Donate
Cancer Trials Ireland > Cancer Trials > Lymphoma & blood cancers

DSSG Group: Lymphoma & blood cancers

BCBI

Name No. For Patients with Purpose
BCBI 24-13

Blood Cancer

The BCNI biobank is called Blood Cancer Biobank Ireland (BCBI). It is a national effort coordinating and standardizing blood cancer biobanking activities at sites in Galway, Dublin, Cork, Limerick and Waterford.

firmMIND INCMOR0208-305

Name No. For Patients with Purpose
firmMIND INCMOR0208-305 24-05

Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).

LOXO-BTK-20022

Name No. For Patients with Purpose
LOXO-BTK-20022 21-44

Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

MRD Study

Name No. For Patients with Purpose
MRD Study 21-23

Patients with Myeloma.

Minimal residual disease (MRD). This is a test performed on the patients DNA at diagnosis by Next Generation Sequencing (NGS), which can detect if there are trace amounts of the cancer remaining in a patient after treatment, and has been shown to be highly predictive of long-term outcomes in several studies.

MK-1026-003

Name No. For Patients with Purpose
MK-1026-003 21-22

Hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM)

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM).

BRUIN CLL-322

Name No. For Patients with Purpose
BRUIN CLL-322 20-21-44

Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

MajesTEC-4

Name No. For Patients with Purpose
MajesTEC-4 23-21

Newly diagnosed multiple myeloma

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

AFFIRM-AL

Name No. For Patients with Purpose
AFFIRM-AL 22-13

The target population for this study are Mayo Stage IV AL amyloid patients

This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients